Protein News and Research

RSS

Proteins are complex molecules that are made up of amino acids. They can be found in every cell in the body, and carry out vital processes that keep human beings alive. Mutations in proteins can lead to a multitude of diseases, the most common being cancer.

Zebrafish provides insight into human melanoma

A transparent member of the minnow family is providing researchers at Weill Cornell Medical College in New York City with insight into human melanoma - a form of skin cancer - that may lead to new or repurposed drug treatments, for skin and other cancers.

19 Jun 2012

Allergy risk in children linked to antibacterials in personal-care products

Exposure to common antibacterial chemicals found in soap, toothpaste, mouthwash and other personal-care products may make children more prone to a wide range of food and environmental allergies, according to new research from Johns Hopkins Children’s Center.

19 Jun 2012

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

FORMA Therapeutics and TGen Drug Development (TD2) today announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations.

19 Jun 2012

Single-dose vaccine for treatment of cocaine addiction

A single-dose vaccine capable of providing immunity against the effects of cocaine offers a novel and groundbreaking strategy for treating cocaine addiction is described in an article published Instant Online in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc.

19 Jun 2012

iBio expands iBioModulator portfolio with allowance of patent for anthrax vaccines

iBio, Inc. today announced that the US Patent Office has allowed patent application 11/706,576 entitled "Bacillus anthracis Antigens, Vaccine Compositions, and Related Methods."

19 Jun 2012

Pfizer receives FDA Complete Response Letter for tafamidis meglumine NDA

Pfizer Inc. announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on its New Drug Application (NDA) for tafamidis meglumine.

19 Jun 2012

NF-κB inhibitors can mitigate cellular damage and prevent aging-related degenerative changes

Age-associated degeneration is caused, at least in part, by accumulated cellular damage, including DNA damage, but how these types of damage drive aging remains unclear. Dr. Paul Robbins and colleagues at the University of Pittsburgh sought to address this question using a mouse model of DNA repair deficiency.

19 Jun 2012

Multi-institutional research uncovers new mechanism for treatment of lung cancer

A multi-institutional research study has uncovered a new mechanism that may lead to unique treatments for lung cancer, one of the leading causes of death worldwide.

18 Jun 2012

A novel candidate gene in human early-onset degenerative ataxias

Researchers at the University of Helsinki and the Folkh-lsan Research Center, Finland, have identified the genetic cause of early-onset progressive cerebellar degeneration the Finnish Hound dog breed. The study, led by Professor Hannes Lohi, revealed a new disease mechanism in cerebellar degeneration. A mutation was identified in the SEL1L gene, which has no previous link to inherited cerebellar ataxias.

18 Jun 2012

Infinity voluntarily stops saridegib Phase 2 trial for chondrosarcoma

Infinity Pharmaceuticals, Inc. today announced interim data from its Phase 2, double-blind, randomized, placebo-controlled study of saridegib (IPI-926) in patients with metastatic or locally advanced, inoperable chondrosarcoma. The primary endpoint of the Phase 2 study was progression-free survival.

18 Jun 2012

Illumina's new patent infringement suit targets Complete Genomics' cPal read technology

Illumina (NASDAQ:ILMN) announced today that the company has filed an additional patent infringement suit against Complete Genomics, Inc. Illumina is seeking all available remedies, including injunctive relief.

From Illumina, Inc. 18 Jun 2012

CMC Biologics' Bothell manufacturing and testing facilities receive cGMP compliance

CMC Biologics, a leading contract manufacturing organization (CMO) known for its technical excellence in process development and cGMP manufacture, has received a Certificate of Good Manufacturing Practice (GMP) Compliance for commercial manufacturing issued by the Medicines and Healthcare products Regulatory Agency (MHRA).

18 Jun 2012

Ambrx, Merck collaborate to develop and commercialize biotherapeutic drug conjugates

Ambrx today announced that the company has entered into a collaboration with Merck to design and develop rationally optimized biologic drug conjugates based on Ambrx's site-specific protein medicinal chemistry technology.

18 Jun 2012

Is curry good for you?

There have been several news stories over the years reporting that curry may be good for us. Most of them refer to a chemical in curry, known as curcumin.

18 Jun 2012

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from the pivotal PACE trial of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with chronic myeloid leukaemia (CML) or Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL), who are resistant or intolerant to dasatinib or nilotinib or who have the T315I mutation.

18 Jun 2012

Scientists discover master regulator gene needed for development of M cells

Scientists have found a master regulator gene needed for the development of M cells, a mysterious type of intestinal cell involved in initiating immune responses.

18 Jun 2012

Patients with NK/T-cell lymphomas might benefit from treatment with JAK inhibitors

A substantial proportion of NK/T-cell lymphomas harbor Janus Kinase 3 gene mutations. Patients with these lymphomas might benefit from treatment with a Janus Kinase inhibitor according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

16 Jun 2012

New approach to drug design may yield more effective and less toxic cancer medicines

A new approach to drug design, pioneered by a group of researchers at the University of California, San Francisco (UCSF) and Mt. Sinai, New York, promises to help identify future drugs to fight cancer and other diseases that will be more effective and have fewer side effects.

16 Jun 2012

Immune system may play a key role in removing Alzheimer's protein

Recent work in mice suggested that the immune system is involved in removing beta-amyloid, the main Alzheimer's-causing substance in the brain. Researchers have now shown for the first time that this may apply in humans.

16 Jun 2012

NextGen commercializes new assay for identification of biomarkers in brain disorders

NextGen Group Plc, the AIM listed company developing its own diagnostics product pipeline and providing diagnostic biomarker development services, announces the commercialisation of a new assay for the identification of diagnostic biomarkers in brain disorders in animal models.

15 Jun 2012

Protein News and Research

Further Reading

Zebrafish provides insight into human melanoma

Allergy risk in children linked to antibacterials in personal-care products

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

Single-dose vaccine for treatment of cocaine addiction

iBio expands iBioModulator portfolio with allowance of patent for anthrax vaccines

Pfizer receives FDA Complete Response Letter for tafamidis meglumine NDA

NF-κB inhibitors can mitigate cellular damage and prevent aging-related degenerative changes

Multi-institutional research uncovers new mechanism for treatment of lung cancer

A novel candidate gene in human early-onset degenerative ataxias

Infinity voluntarily stops saridegib Phase 2 trial for chondrosarcoma

Illumina's new patent infringement suit targets Complete Genomics' cPal read technology

CMC Biologics' Bothell manufacturing and testing facilities receive cGMP compliance

Ambrx, Merck collaborate to develop and commercialize biotherapeutic drug conjugates

Is curry good for you?

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

Scientists discover master regulator gene needed for development of M cells

Patients with NK/T-cell lymphomas might benefit from treatment with JAK inhibitors

New approach to drug design may yield more effective and less toxic cancer medicines

Immune system may play a key role in removing Alzheimer's protein

NextGen commercializes new assay for identification of biomarkers in brain disorders

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News